Every large-scale pharmaceutical acquisition rests on a single economic fact: the target’s revenue is a function of its legal right […]
Drug Patent Due Diligence in Pharma M&A: The Complete IP Valuation Playbook Read Post »
The LATAM Generic Drug Playbook: Patent Cliffs, Regulatory Arbitrage, and Why Most Multinationals Get It Wrong The Latin American generic
Part 1: The Economics of Biopharma Risk: Why Standard Research Isn’t Enough The cost to bring a new molecular entity
Introduction: The Patent Cliff Is Yesterday’s Problem The pharmaceutical industry spent decades obsessing over the patent cliff, that moment when
Drug Exclusivity Decoded: The Complete Playbook for Maximum Market Protection Read Post »
How to quantify pharmaceutical patent assets, structure patent-backed financing, and convert exclusivity data into investment-grade capital strategies 1. Why Pharma
Drug Patent IP Valuation & Financing: The Definitive Analyst’s Playbook Read Post »
Formulary management is a nine-figure business problem dressed up as a clinical workflow. Every Pharmacy & Therapeutics (P&T) committee in
Part I: The Strategic Imperative – Patent Risk as a Financial Variable {#part-i} The $2.6 Billion Problem No Pipeline Model
1. The Patent Bargain, Recalibrated: What the Ruling Actually Did On May 18, 2023, the U.S. Supreme Court issued a
Why IP Benchmarking Is a Revenue Function, Not a Legal One A composition of matter patent on a new drug
Sign in or create a free account to read this DrugPatentWatch article
